COMMUNIQUÉS West-GlobeNewswire

Hapbee Expands Community Monetization with Gift-A-Friend and Referral Programs
08/08/2025
Designed by Hapbee's Chief Innovation Officer and NBA Finals MVP Jaylen Brown to build upon the concept of giving, the new Gift-A-Friend and Referral Programs empower members to share wellness and earn rewards directly [...]
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
08/08/2025
WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced an update on institutional ownership of the Company’s outstanding common stock, as [...]
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
08/08/2025
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of [...]
Spectral Medical Announces Second Quarter and Provides Corporate Update
08/08/2025
Topline Tigris results expected to be released around mid-August 2025 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing [...]
Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results
08/08/2025
Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis (1) , compared to Q2 2024 Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0 [...]
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
08/08/2025
SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
08/08/2025
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation [...]
Vaxart CEO Issues Letter to Stockholders
08/08/2025
- Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“ [...]
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
08/08/2025
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated CORE-008 [...]
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
08/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
08/08/2025
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, [...]
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
08/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, [...]
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
08/08/2025
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET – SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology [...]
Ultrack Systems Inc. (OTC: MJLB) Adds PUR Botanicals as Strategic Partner in PUR Rx Joint Venture: A Fully Vertically Integrated Natural Health Pharmacy Targeting Explosive Growth
08/08/2025
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB), a Canadian-based leader in wellness-focused technology and compliance-driven ventures, is proud to announce the addition of PUR Botanicals Ltd [...]
Enovis to Participate in Upcoming Investor Conferences
08/08/2025
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08/08/2025
Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Sanuwave Announces Q2 FY2025 Financial Results
08/08/2025
Q2 2025 revenues were $10.2 million , up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3% , versus 73.2% in Q2 2024. GAAP Operating [...]
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
08/08/2025
Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 million SERB Pharmaceuticals to acquire Y-mAbs in $412.0 [...]
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
08/08/2025
Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basis Total Rare Disease quarterly net revenues of $104.0 million, which [...]

Pages